Skip to main content
SpringerLink
Log in

Lenograstim shows potential in a wide range of neutropenic and other indications

  • New drugs and disease management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Yarker YE, Goa KL. Lenograstim: a review of its pharmacological properties and therapeutic efficacy in neutropenia and related clinical settings. Drugs 1995; 49: 767–93

    Article  PubMed  Google Scholar 

  2. Seymour A-M, de Campos E, Thatcher N, et al. A single-blind, randomised, vehicle-controlled dose-finding study of recombinant granulocyte colony-stimulating factor (lenograstim) in patients undergoing chemotherapy for solid cancers and lymphoma. Eur J Cancer 1995; 31A: 2157–63

    Article  PubMed  CAS  Google Scholar 

  3. Dunn CJ, Goa KL. Lenograstim: an update of its pharmacological properties and use in chemotherapy-induced neutropenia and related clinical settings. Drugs 2000; 59(3): 681–717

    Article  PubMed  CAS  Google Scholar 

  4. Ema H, Suda T, Nagayoshi K, et al. Target cells for granulocyte colony-stimulating factor, interleukin-3, and interleukin-5 in differentiation of pathways of neutrophils and eosinophils. Blood 1990; 76(10): 1956–61

    PubMed  CAS  Google Scholar 

  5. Watts MJ, Addison I, Ings SJ, et al. Optimal timing for collection of PBPC after glycosylated G-CSF administration. Bone Marrow Transplant 1998; 21: 365–8

    Article  PubMed  CAS  Google Scholar 

  6. Chevallier B, Chollet P, Merrouche Y, et al. Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. J Clin Oncol 1995; 13: 1564–71

    PubMed  CAS  Google Scholar 

  7. Gisselbrecht C, Haioun C, Lepage E, et al. Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin’s lymphoma: factors influencing chemotherapy administration. Leuk Lymphoma 1997; 25: 289–300

    PubMed  CAS  Google Scholar 

  8. Schröder CP, de Vries EGE, Mulder NH, et al. Prevention of febrile leucopenia after chemotherapy in high-risk breast cancer patients: no significant difference between granulocyte-colony stimulating growth factor or ciprofloxacin plus amphotericin B. J Antimicrob Chemother 1999; 43: 741–3

    Article  PubMed  Google Scholar 

  9. Bonadonna G, Pannuti F, Robustelli G, et al. Phase III study comparing standard dose FNC (5-fluorouracil, mitoxantrone, cyclophosphamide) versus dose-intensive FNC + rHuG-CSF (lenograstim) versus time-intensive FNC + lenograstim in advanced breast cancer (ABC) patients: preliminary results of the CSF-001 study [abstract]. 33rd Proceedings of the American Society of Clinical Oncology; 1997 May 17; Denver; 16: 149

    Google Scholar 

  10. Garrone O, Venturini M, Del Mastro L, et al. Dose-intensity and dose density in metastatic breast cancer: final results from GONOMIG-3 randomized study [abstract]. Tumori 1998; 84 Suppl. 1: 58

    Google Scholar 

  11. Gisselbrecht C, Prentice HG, Bacigalupo A, et al. Placebo-controlled phase III trial of lenograstim in bone-marrow transplantation. Lancet 1994; 343: 696–700

    Article  PubMed  CAS  Google Scholar 

  12. Linch DC, Milligan DW, Winfield DA, et al. G-CSF after peripheral blood stem cell transplantation in lymphoma patients significantly accelerated neutrophil recovery and shortened time in hospital: results of a randomized BNLI trial. Br J Haematol 1997; 1199(4): 933–8

    Article  Google Scholar 

  13. Campilho F, Campos A, Vaz CP, et al. Filgrastim versus lenograstim after allogeneic stem cell transplantation: a prospective randomised study [abstract]. Bone Marrow Transplant 1999; 23 Suppl. 1: S81

    Google Scholar 

  14. Gluckman E, Rokicka-Milewska R, Gordon-Smith EC, et al. Results of a randomized study of glycosylated rHuG-CSF lenograstim in severe aplastic anaemia [abstract]. Blood 1998; 92 (Suppl. 1 Pt 1): 376

    Google Scholar 

  15. Rubino C, Laplanche A, Patte C, et al. Cost-minimization analysis of prophylactic granulocyte colony-stimulating factor after induction chemotherapy in children with non-Hodgkin’s lymphoma. J Natl Cancer Inst 1998; 90: 750–5

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lenograstim shows potential in a wide range of neutropenic and other indications. Drugs Ther. Perspect 17, 1–5 (2001). https://doi.org/10.2165/00042310-200117010-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200117010-00001

Keywords

Search

Navigation